Absence of dystrophin in two patients with Becker type Xp21 muscular dystrophy
Neuroscience Letters, ISSN: 0304-3940, Vol: 147, Issue: 1, Page: 37-40
1992
- 4Citations
- 6Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Two patients with Xp21 muscular dystrophy Becker type showed absence of dystrophin in muscle biopsy tested with 4 antibodies (polyclonal anti-60 kDa, monoclonal against the rod domain, the C-terminus and the N-terminus). DNA analysis did not detect any deletion in one patient and demonstrated deletion of exons 3–7 in the other. The cases represent an exception to the strict correlation between the dystrophin pattern in muscle biopsy and the clinical course of the disease: in fact both the patients are still walking at 14 and 15 years respectively. The possibility of similar cases must be considered not only in the prognosis of Xp21 muscular dystrophy but the more so in the evaluation of therapeutical trials.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/0304394092907694; http://dx.doi.org/10.1016/0304-3940(92)90769-4; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0026465694&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/1480320; https://linkinghub.elsevier.com/retrieve/pii/0304394092907694; http://dx.doi.org/10.1016/0304-3940%2892%2990769-4; https://dx.doi.org/10.1016/0304-3940%2892%2990769-4
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know